Antiviral Compounds

Abstract

The present application provides compounds and methods of treating viral infections, including viral infections caused by HIV or HTLV.

1 - 31 . (canceled) 
     
     
         32 . A method of treating a human immunodeficiency virus (HIV) infection, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         33 . The method of  claim 32 , wherein the compound is: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         34 . The method of  claim 32 , wherein the compound is: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         35 . The method of  claim 32 , wherein the compound is: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         36 . The method of  claim 32 , wherein the compound is: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         37 . The method of  claim 32 , wherein the compound is: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         38 . The method of  claim 32 , comprising administering to the subject another antiviral therapeutic agent useful in treating an HIV infection, or a pharmaceutically acceptable salt thereof. 
     
     
         39 . The method of  claim 38 , wherein the antiviral therapeutic agent useful in treating an HIV infection is selected from a non-nucleoside reverse transcriptase inhibitor (NNRTI), a nucleoside analog reverse transcriptase inhibitor (NRTI), an HIV integrase inhibitor, and a protease inhibitor. 
     
     
         40 . A method of treating a human T-cell leukemia-lymphoma virus (HTLV) infection, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         41 . The method of  claim 40 , wherein the compound is 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         42 . The method of  claim 40 , wherein the compound is 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         43 . The method of  claim 40 , wherein the compound is 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         44 . The method of  claim 40 , wherein the compound is 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         45 . The method of  claim 40 , wherein the compound is 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         46 . The method of  claim 40 , comprising administering to the subject another antiviral therapeutic agent useful in treating an HTLV infection, or a pharmaceutically acceptable salt thereof. 
     
     
         47 . The method of  claim 46 , wherein the antiviral therapeutic agent useful in treating an HTLV infection is selected from prosultiamine, azacytidine, tenofovir disoproxil, and cepharanthine, or a pharmaceutically acceptable salt thereof. 
     
     
         48 . A method of treating a human T-cell leukemia-lymphoma virus (HTLV) infection, the method comprising administering to a subject in need thereof a therapeutically effective amount of darunavir or indinavir, or a pharmaceutically acceptable salt thereof. 
     
     
         49 . The method of  claim 48 , comprising administering to the subject a therapeutically effective amount of darunavir, or a pharmaceutically acceptable salt thereof. 
     
     
         50 . The method of  claim 48 , further comprising administering to the subject another antiviral therapeutic agent useful in treating an HTLV infection, or a pharmaceutically acceptable salt thereof. 
     
     
         51 . The method of  claim 50 , wherein the antiviral therapeutic agent useful in treating an HTLV infection is selected from prosultiamine, azacytidine, tenofovir disoproxil, and cepharanthine, or a pharmaceutically acceptable salt thereof.